This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pepine, C. J. Articles by Cooper-DeHoff, R. M. Search for Related Content PubMed PubMed Citation Articles by Pepine, C. J. Articles by Cooper-DeHoff, R. M.

Cardiovascular therapies and risk for development of diabetes

^* Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA

View larger version (48K): [in a new window]   Figure 1 Incidence of new diabetes according to study and drug treatment. *The risk ratio presented is either the relative risk or hazard ratio and 95% confidence interval (CI), as published. Mean years of follow-up. With or without background beta-blockers (BBs) and diuretics. The relative risk and 95% CI were estimated from data provided in publication, using the Mantel-Haenszel method. ||Reported as the percentage of patients with fasting blood sugar at year 4 (C, n = 2,606; A, n = 1,567; L, n = 1,464). ¶Total follow-up for each patient. Solid bars = BBs/diuretics; open bars = angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB)/calcium antagonist (CA). DB = double blind; PROBE = prospective randomized open blinded end point. CAPPP = Captopril Prevention Project; INSIGHT = Intervention as a Goal in Hypertension Treatment; LIFE = Losartan Intervention For Endpoint reduction; ALLHAT = Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial; ANBP2 = Second Australian National Blood Pressure Study; ALPINE = Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation; CHARM = Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity; INVEST = International Verapamil-Trandolapril Study.

View larger version (32K): [in a new window]   Figure 2 Percent reduction of new diabetes in randomized clinical trials categorized by treatment groups containing predominantly either an ACE inhibitor or ARB (open bars), CA plus either an ACE inhibitor or ARB (striped bars), or CA alone (solid bars). The comparator groups contained predominantly either BBs and/or thiazide diuretics. Abbreviations as in Figure 1.